New stem cell population may help repair teeth

Researchers have discovered that crosstalk of a newly discovered stem cell population with quiescent stem cells may help repair teeth in the future.

Read more

Bayer bags iPSC specialist BlueRock Therapeutics

Bayer has widened its pipeline in neurology, cardiology, and immunology by acquiring induced pluripotent stem cell specialist BlueRock Therapeutics.

Read more

Liquid biopsy identifies residual breast cancer

Using a platform tailored to patients’ specific cancer mutations, British and US researchers for the first time detected residual disease in breast cancer patients.

Read more

Immunic appoints Sanjay S. Patel as CFO

Immunic, Inc., a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Sanjay S. Patel, CFA, as Chief Financial Officer, effective July 15, 2019. Mr. Patel replaces Tamara A. Seymour, who has served as the company’s Interim Chief Financial Officer since April 26, 2019.

Read more

Novo Holdings puts $72m in Lanzatech

Novo Holdings A/S (Novo Holdings) invests $72m in LanzaTech to support development of the company’s sustainable fuels and chemicals platform
Read more

Google maps for tumours and organs

German researchers have developed a software that allows to manage and correct the huge amount of data generated by 3D reconstruction of tumours or organs using light sheet microscopy.
Read more

Transgene’s licenced oncolytic virus fails in Phase III

SillaJen, the licensor for French immunoncology specialist Transgene SA, has stopped enrolment into the Phase III Phocus trial after an Independent Data Review Comittee predicted the study endpoint won’t be met.

Read more

Pieris Pharmaceuticals appoints Dr. Maya Said

Pieris Pharmaceuticals, Inc. today announced that Maya R. Said, Sc.D., has joined the Company’s Board of Directors.

Read more

Wellington Partners launch €210m Life Sciences fund

Wellington Partners has closed its largest Life Sciences Fund ever. The VC specialist outperformed its intial target of raising €120m to €150m and closed at €210m.

Read more

Alizé Pharma 3 bags largest EU financing so far

Venture Captital specialist LSP led a €67m Series A financing in peptide developer Alizé Pharma 3.

Read more